NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۲۰ • واحد: years
حداقل ۱۰ — حداکثر ۷۰ • واحد: kg/m²
حداقل ۱ — حداکثر ۲۰۰۰ • واحد: IU/L
حداقل ۱ — حداکثر ۲۰۰۰ • واحد: IU/L
حداقل ۱۰ — حداکثر ۸۰۰ • واحد: ×10⁹/L
حداقل ۱ — حداکثر ۶ • واحد: g/dL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- F0-F2-10–-1.455
- Indeterminate-1.455–0.676
- F3-F40.676–10
The NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score calculates assessing gastrointestinal disease severity, endoscopic intervention urgency, and rebleeding risk. Key inputs include age. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates amount of scarring in the liver based on various lab tests. Distinguishes between patients with nonalcoholic fatty liver disease who have (F3-F4) and do not have (F0-F2) advanced fibrosis.
Clinical Indication
The NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score is indicated for bedside clinical practice to support Estimates amount of scarring in the liver based on various lab tests. Distinguishes between patients with nonalcoholic fatty liver disease who have (F3-F4) and do not have (F0-F2) advanced fibrosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.
Limitations & Contraindications
Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration.
Clinical Pearls & Action Plan
Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy.
NAFLD Score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m²) + 1.13 × hyperglycemia (yes=1, no=0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×10⁹/L) - 0.66 × albumin (g/dL)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | float | Yes | Patient age in years(years) |
| bmi | float | Yes | Body Mass Index calculated as weight(kg) / height(m)²(kg/m²) |
| hyperglycemia | string | Yes | Presence of impaired fasting glucose (IFG) or diabetes mellitus |
| ast | float | Yes | Aspartate aminotransferase (AST) level(IU/L) |
| alt | float | Yes | Alanine aminotransferase (ALT) level(IU/L) |
| platelet_count | float | Yes | Platelet count(×10⁹/L) |
| albumin | float | Yes | Serum albumin level(g/dL) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| -10–-1.455 | F0-F2 | Absence of significant fibrosis |
| -1.455–0.676 | Indeterminate | Indeterminate zone |
| 0.676–10 | F3-F4 | Presence of significant fibrosis |
Evidence-Based References (EBM)
- Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007 Apr;45(4):846-54. doi: 10.1002/hep.21496.DOI: 10.1002/hep.21496
- McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010 Sep;59(9):1265-9. doi: 10.1136/gut.2010.216077.DOI: 10.1136/gut.2010.216077